Skip to main content
. 2022 Feb 21;35(3):275–280. doi: 10.20524/aog.2022.0699

Figure 1.

Figure 1

Primary outcomes (VDZ dose escalation and VDZ discontinuation) and secondary outcomes (SFCR, endoscopic remission, CRP normalization) displayed graphically, stratified by BMI <30 kg/m2 or BMI ≥30 kg/m2

*Data not available for 62 patients; **Data not available for 45 patients

VDZ, vedolizumab; CRP, C-reactive protein; SFCR, steroid-free clinical remission; BMI, body mass index